It is composed of three parts: Akeso Pharma Co., Ltd (Akeso Pharma), AD Pharmaceuticals (AD Pharma) and Akeso Longyue. Akeso Pharma is equipped with a complete set of Cytiva FlexFactoryTM drug production equipment, a BOSCH automatic preparation filling line, etc., with a planned total ...
AD Pharmaceuticals Co., Ltd.Established in December 2016, AD Pharmaceuticals Co., Ltd. (AD Pharmaceuticals) is a subsidiary of Akeso, Inc. (9926.HK), the pioneer in biologics innovation in China. AD Pharmaceuticals is an innovative biopharmaceutical company integrating antibody drug development, ...
Jun 02, 2023,Akeso Inc. (9926. HK, "Akeso") announced today that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications 1) primary hypercholesterolemia and m...
This BioChina Summit is themed of “GO FORWARD·Make Innovation Walk with More Power”, focusing on innovative projects and bellwether of next-generation biotech industry development, creating sustainable innovation pattern with quick results, promoting Chinese pharmaceuticals innovation and cooperation. Bisp...
View original content to download multimedia:https://www.prnewswire.com/news-releases/akesos-ivonescimab-pd-1vegf-bsabs-granted-breakthrough-therapy-designation-by-china-nmpa-for-the-treatment-of-advanced-nsclc-301655654.html Source: Akeso, Inc. ...
HONG KONG, Feb. 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaborati...
AK104 is a potential next-generation, first-in-class humanized IgG1 tetrameric bi-specific antibody drug candidate that is developed in house by Akeso,Inc., is designed to achieve preferential binding to tumor infiltrating lymphocytes rather than normal peripheral tissue lymphocytes. Based on Akeso'...
Akeso” or the “Company”, stock code: 9926.HK) is pleased to announce today that, Akeso is awarded as "Most Honored Company" in the "2021 All-Asia Executive Team" survey published byInstitutional Investor, and is ranked top 3 in all five categories in the Healthcare & Pharmaceuticals ...
It is composed of three parts: Akeso Pharma Co., Ltd (Akeso Pharma), AD Pharmaceuticals (AD Pharma) and Akeso Longyue. Akeso Pharma is equipped with a complete set of Cytiva FlexFactoryTM drug production equipment, a BOSCH automatic preparation filling line, etc., with a planned total ...
AD Pharmaceuticals Co., Ltd.Established in December 2016, AD Pharmaceuticals Co., Ltd. (AD Pharmaceuticals) is a subsidiary of Akeso, Inc. (9926.HK), the pioneer in biologics innovation in China. AD Pharmaceuticals is an innovative biopharmaceutical company integrating antibody drug development, ...